Skip to content

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Gilead Sciences logo
Gilead SciencesGILD
5.3%+1.1pp
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
-16.1%-7.4pp
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-54.7%-16.8pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-24.5%-5.5pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-18%-4.7pp

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Calculated from Kyverna Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s earnings yield?
Kyverna Therapeutics, Inc. (KYTX) reported earnings yield of -30% in Q1 2026.
How has Kyverna Therapeutics, Inc.'s earnings yield changed year-over-year?
Kyverna Therapeutics, Inc.'s earnings yield increased by 82.8% year-over-year, from -174.5% to -30%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.